A division of Fougera Pharmaceuticals Inc., this company focuses on developing and providing FDA-approved treatments for vulvovaginal candidiasis, addressing needs in the rare disease space.
0
Orphan Designations
7
FDA Approvals
Latest: TERCONAZOLE VAGINAL CREAM 0.8% (2004)
0
Active Trials
1
Rare Diseases
across 3 areas
0
News (30d)
Quiet
E. Fougera & Co. a division of Fougera Pharmaceuticals Inc. is a company with 0 orphan drug designations across 1 rare disease, including 7 FDA-approved therapies.
Disease-by-disease pipeline progression from orphan designation through clinical trials to FDA approval.
Source: FDA Orphan Drug Designations, ClinicalTrials.gov, Drugs@FDA
| Disease | Drug(s) | Stage |
|---|---|---|
| vulvovaginal candidiasis | TERCONAZOLE VAGINAL CREAM 0.8% | Des.TrialAppr. |
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio
0% of portfolio targets high unmet need diseases
0
overlap in 2+ diseases
0/1
candidate diseases
0
avg importance: 0
0
affecting portfolio